Flexible Flat-Rate Plans

Flat-rate pricing for predictable budgeting

Short-term plans for project- or client-based billing

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 6,172,233

« Back to Dashboard
Patent 6,172,233 protects PAXIL and is included in one NDA. There has been one Paragraph IV challenge on Paxil.

Protection for PAXIL has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has one patent family member in one country.

This patent has expired prematurely due to non-payment of maintenance fees. See details below.

Summary for Patent: 6,172,233

Title: Process for making paroxetine
Abstract:Compounds of structure (2) are prepared by reaction of an arecoline analogue of structure(4) with an organometallic compound containing an X-substituted phenyl group, such as a compound of structure (3). ##STR1## Suitably the compound of structure (3) is a Grignard reagent, where M is magnesium and Y is a halogen atom, or M may be a Group II metal and Y is a halogen atom or a second X-substituted phenyl group. When structure (3) is a Grignard reagent, the reaction is carried out either in a suitable non-ether solvent, typically a hydrocarbon or a non-reactive chlorinated hydrocarbon, or in a mixture of such a solvent with diethyl ether. Compounds of structure (2) are important intermediates in the preparation of inter alia paroxetine.
Inventor(s): Ward; Neal (Tonbridge, GB)
Assignee: SmithKline Beecham plc (Brentford, GB)
Application Number:09/007,475
Patent Claim Types:
see list of patent claims
Compound; Process;
Patent Metrics:
Source: PatentQuant.com
Field: Organic fine chemistry
Back Citations: 11th percentile
Forward Citations: 0th percentile

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Apotex Technologies
paroxetine hydrochloride
CAPSULE;ORAL020885-001Oct 9, 1998DISCNNo6,172,233*PEDJul 15, 2018Y
Apotex Technologies
paroxetine hydrochloride
CAPSULE;ORAL020885-002Oct 9, 1998DISCNNo6,172,233*PEDJul 15, 2018Y
Apotex Technologies
paroxetine hydrochloride
CAPSULE;ORAL020885-003Oct 9, 1998DISCNNo6,172,233*PEDJul 15, 2018Y
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Premature patent expiration for: 6,172,233

Expiration due to failure to pay maintenance fee

Patent Number Expiration Date
6,172,233 January 09, 2013

Foreign Priority and PCT Information for Patent: 6,172,233

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom9700690Jan 15, 1997

International Patent Family for Patent: 6,172,233

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
United Kingdom9700690<disabled in preview>
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.